Drug name - Myfembree

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(1 year, 1 month from now)

US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(1 year, 1 month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(1 year, 2 months from now)

US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG;0.5MG;40MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in